Roberts M Scot 4

What Happened
Roberts M. Scot, Chief Scientific Officer of Altimmune, had 14,600 restricted stock units (RSUs) convert to common shares on January 25, 2026 (reported on Form 4 filed Jan 27, 2026). The conversion had no exercise price. To cover tax withholding, 4,373 of those shares were surrendered/withheld at $5.50 per share, yielding approximately $24,052. Net shares delivered to Roberts from this vesting were 10,227 (14,600 vested − 4,373 withheld).

Key Details

• Transaction date: January 25, 2026; Form 4 filed January 27, 2026 (filed within the normal 2-business-day window).
• Primary codes: M = exercise/conversion of derivative (RSU conversion); F = shares surrendered to cover taxes.
• Shares vested/converted: 14,600 shares @ $0.00 (no exercise price).
• Shares withheld for taxes: 4,373 shares @ $5.50 = $24,052 (surrendered to issuer).
• Net shares received by insider from the vesting: 10,227 shares.
• Shares owned after the transaction: not disclosed in the supplied filing.
• Footnotes: RSUs represent contingent rights to one share when vested; they vest in substantially equal annual installments over 4 years from Jan 25, 2024, and can be withheld to cover taxes.

Context
This was an RSU vesting event (conversion of restricted stock units), not an open-market purchase or voluntary sale. The withholding of shares to satisfy tax obligations is routine and does not necessarily indicate a change in the insider’s view of the company. For derivative transactions like RSU conversions, the M code indicates conversion to common stock; the F code indicates shares were surrendered for tax withholding.